Cold ischemia augments allogeneic-mediated injury in rat kidney allografts.
BACKGROUND
Some clinical studies demonstrate that kidney grafts with prolonged cold ischemia experience early acute rejection more often than those with minimal ischemia. The mechanism, however, is putative. Therefore, the aim of this study was to unravel the impact of ischemia on the immune response in rat kidney allografts compared with that in isografts.


METHODS
To induce ischemic injury, donor kidneys were preserved for 24 hours in 4 degrees C University of Wisconsin solution before transplantation. No immunosuppression was administered. The histomorphology according to the BANFF criteria for acute rejection and infiltrating cells were assessed at days 1, 2, 3, 4, 6, and 8 post-transplantation.


RESULTS
In allografts, exposure of the kidney to ischemia led to a significantly earlier onset of interstitial cell infiltration and tubulitis compared with nonischemic allografts. The BANFF score of interstitial cell infiltration was 1 +/- 0 vs. 0.25 +/- 0.29 at day 3 and 2 +/- 0 vs. 1.25 +/- 0.25 at day 4. In contrast, in isografts, the effect of ischemia on the histology was not significant. From day 6, the histologic differences between ischemic and nonischemic grafts disappeared. Ischemia led to a more intense expression of P-selectin (day 1), intercellular adhesion molecule-1 (ICAM-1; day 2), and major histocompatibility complex (MHC) class II on endothelium and proximal tubular cells (day 2) in both allografts and isografts. Concurrently with the up-regulated ICAM-1 and MHC expression, significantly more CD4(+) cells and macrophages infiltrated the ischemic allografts at days 2 and 3 and the ischemic isografts at day 4. Importantly, the influx of these cells after ischemia was significantly greater in allografts than in isografts.


CONCLUSIONS
Cold ischemia augments allogeneic-mediated cell infiltration in rat kidney allografts. The earlier onset of acute rejection in 24-hour cold preserved allografts may be prevented by better preservation or treatment using tailored immunosuppression.
Kouwenhoven
E A
EA
Department of Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands. debruin@heel.fgg.eur.nl
de Bruin
R W
RW
Bajema
I M
IM
Marquet
R L
RL
Ijzermans
J N
JN
D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000473:pathology; D015925:Cryopreservation; D000949:Histocompatibility Antigens Class II / Q000378:metabolism; D007150:Immunohistochemistry; D018799:Intercellular Adhesion Molecule-1 / Q000378:metabolism; D007668:Kidney / Q000378:metabolism / Q000473:pathology*; D016030:Kidney Transplantation; D008264:Macrophages / Q000473:pathology; D008297:Male; D019007:P-Selectin / Q000378:metabolism; D051381:Rats; D011914:Rats, Inbred BN; D014184:Transplantation, Homologous; D014185:Transplantation, Isogeneic
D000949:Histocompatibility Antigens Class II; D019007:P-Selectin; D018799:Intercellular Adhesion Molecule-1